Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 22;8:77. doi: 10.1038/s41420-022-00850-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 8 — A RT-qPCR to determine the expression of UVRAG, ATG5, and Wnt5a after overexpressing SMURF1. B The expression of UVRAG, ATG5, and Wnt5a after overexpression of SMURF1 detected by Western blot analysis. C The binding between SMURF1 and UVRAG assessed by Co-IP analysis. D The effect of SMURF1 on the ubiquitination of UVRAG measured by Co-IP analysis. E The effect of concomitant treatment of rapamycin or recombinant Wnt5a and sh-UVRAG on the expression of ATG5, Wnt5a assessed by Western blot analysis. F RT-qPCR to determine the expression of hepatocyte-related genes in BMSCs after 14 days of simultaneous treatment of rapamycin or recombinant Wnt5a and sh-UVRAG. G ELISA assay to detect the ALB content in culture supernatant of BMSCs after 14 days of concomitant treatment of rapamycin or recombinant Wnt5a and sh-UVRAG. H PAS staining to detect the accumulation of glycogen in BMSCs after 14 days of simultaneous treatment of rapamycin or recombinant Wnt5a and sh-UVRAG. *p < 0.05 vs. BMSCs transfected with oe-NC/sh-NC; ^#p < 0.05 vs. BMSCs transfected with sh-UVRAG. The cell experiments were repeated three times.